Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Amaal AlDakheel"'
Autor:
Saeed Bohlega, Zainah Al-Qahtani, Francisco J. Guzmán-Vega, Reshmi Ramakrishnan, Ali Abusrair, Haya Aldosari, Amaal AlDakheel, Salma Al-Qahtani, Dorota Monies, Stefan Arold
Publikováno v:
Wednesday, April 26.
Publikováno v:
Thursday, April 27.
Autor:
Saeed Bohlega, Ali H. Abusrair, Zainah Al-Qahtani, Francisco J. Guzmán-Vega, Reshmi Ramakrishnan, Haya Aldosari, Amaal Aldakheel, Salma Al-Qahtani, Dorota Monies, Stefan T. Arold
Publikováno v:
Parkinsonism & Related Disorders. 108:105323
Autor:
Amaal AlDakheel, Elena Moro, Andres M. Lozano, Yu Yan Poon, Cindy Zadikoff, Clement Hamani, Anthony E. Lang, Emma Scelzo
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 88:613-616
Axial signs and cognitive disorders are the major source of disability in progressive supranuclear palsy (PSP). Deep brain stimulation (DBS) of the pedunculopontine nucleus (PPN), a structure involved in locomotion and posture control, has showed to
Autor:
Ekaterina Rogaeva, Amaal AlDakheel, Carmen Gasca-Salas, Barbara S. Connolly, Farah Kausar, Sam Woong Kim, Caroline M. Tanner, Naomi P. Visanji, Kaviraj Udupa, Connie Marras, Birgitt Schüle, Achinoam Faust-Socher, Anthony E. Lang, Drew S. Kern, Samuel M. Goldman, Ruksana Azhu Valappil, Jennifer Jain, J. William Langston, Tiago A. Mestre, Grace S. Bhudhikanok, Elizabeth Slow, Taneera Ghate
Publikováno v:
Movement Disorders. 32:610-614
Background Heart rate variability is reduced in idiopathic PD, indicating cardiac autonomic dysfunction likely resulting from peripheral autonomic synucleinopathy. Little is known about heart rate variability in leucine-rich repeat kinase 2-associate
Publikováno v:
Alzheimer disease and associated disorders. 33(2)
Objectives The main purpose of this study was to investigate 4 methods of eliciting subjective cognitive complaints (SCCs) in Parkinson's disease (PD) patients without dementia and determine the relationship between their SCC and cognitive performanc
Autor:
Elizabeth Slow, Amaal AlDakheel, Drew S. Kern, Max A. Little, Carmen Gasca-Salas, Barbara S. Connolly, Naomi P. Visanji, Jennifer Jain, Athanasios Tsanas, Tiago A. Mestre, Siddharth Arora, Achinoam Faust-Socher, Anthony E. Lang, Connie Marras
Publikováno v:
Arora, S, Visanji, N P, Mestre, T A, Tsanas, A, AlDakheel, A, Connolly, B S, Gasca-Salas, C, Kern, D S, Jain, J, Slow, E J, Faust-Socher, A, Lang, A E, Little, M A & Marras, C 2018, ' Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease ', Journal of Parkinson's disease . https://doi.org/10.3233/JPD-181389
We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idio
Autor:
Amr M. Al-Saif, Brian F. Meyer, Hussam Abou-Al-Shaar, Edward Cupler, Saeed Bohlega, Balsam S. Bohlega, Huda Alajlan, Amaal AlDakheel, Dorota Monies
Publikováno v:
Parkinsonismrelated disorders. 64
Introduction ADCY5-related hyperkinesia encompasses a heterogeneous group of phenotypes, including paroxysmal chorea, myoclonus, and dystonia. The disease is attributed to mutations of ADCY5, which encodes an adenylate cyclase enzyme. The disease can
Autor:
Drew S. Kern, George Tomlinson, Tiago A. Mestre, Connie Marras, Jennifer Jain, Andrew S P Lim, Naomi P. Visanji, Anthony E. Lang, Ekaterina Rogaeva, Achinoam Faust-Socher, Barbara S. Connolly, Lieneke van den Heuvel, Amaal AlDakheel, Carmen Gasca-Salas, Margarita Pondal, Elizabeth Slow, Taneera Ghate, Jana Huang
Publikováno v:
Journal of Parkinson's Disease, 8, 1, pp. 131-139
Journal of Parkinson's Disease, 8, 131-139
Journal of Parkinson's Disease, 8, 131-139
BACKGROUND With recent advances in the search for disease-modifying therapies for Parkinson's disease (PD) the importance of identifying prodromal markers becomes greater. Non-manifesting LRRK2 mutation carriers (NMC) are at risk for developing PD, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f9a7aeac6fd1efb2bf7577d09df082d
https://doi.org/10.3233/JPD-171151
https://doi.org/10.3233/JPD-171151
Publikováno v:
Neurotherapeutics. 11:6-23
Parkinson disease is an inexorably progressive neurodegenerative disorder. Multiple attempts have been made to establish therapies for Parkinson disease which provide neuroprotection or disease modification—two related, but not identical, concepts.